Filter posts

CNBC Commentary: Hedge funds, 'reverse trolls' crushing biopharma innovation

Patents are the lifeblood of medical innovation. They are the cornerstone that enables companies to …

Understanding the Wider Implications of HR 9: Patent Reform's Impact on Agriculture

The House Judiciary Committee recently approved H.R. 9, the Innovation Act, legislation they hoped would …

IP Sessions at BIO 2015: The Evolving Landscape of Patentable Subject Matter

The IP Track at BIO 2015 had a number of incredible educational sessions concerning the …

This Independence Day, Let’s Thank the Inventors

Happy Birthday AMERICA! That’s right, this Saturday is July 4. And yes, that means what …

IP Sessions at BIO 2015: The Impact of the Inter Partes Review on (BIO)Pharma

The Intellectual Property Track at the BIO International Convention was a chance for IP thought …

FDA Acts on Biosimilars

The Biologics Price Competition and Innovation Act (BPCIA) deferred to the Food and Drug Administration …

Biosimilars at the Federal Circuit – Can the Parties Be Compelled to Dance?

In 2009, Congress passed the Biologics Price Competition and Innovation Act (“BPCIA”), which for the first …

11 Days Until BIO 2015: IP Networking and Meetup Opportunities

This year’s BIO International Convention is fast approaching, with plenty of opportunities for the best …

IP Sessions at the 2015 BIO International Convention

This year’s BIO International Convention will be host to educational sessions on the latest issues …

BIO Deputy General Counsel Testifies on Patent Reform

On Wednesday, March 18, BIO’s Deputy Counsel for Intellectual Property, Hans Sauer, testified in front …